Abdalla, S;
Compagnucci, A;
Bamford, A;
Chan, MK;
Ramos, JT;
Riault, Y;
Saidi, Y;
... Welch, S; + view all
(2025)
Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents.
AIDS
10.1097/QAD.0000000000004223.
(In press).
![[thumbnail of assessment_of_the_steady_state_drug_drug.702.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
assessment_of_the_steady_state_drug_drug.702.pdf - Accepted Version Access restricted to UCL open access staff until 4 May 2026. Download (1MB) |
Abstract
Objectives: DTG is primarily metabolized by the UDP-glycosyltransferase (UGT) 1A1, and to a lesser extent by the cytochrome P450 (CYP) 3A4. Co-administration of DRV/r has been reported to decrease DTG plasma concentrations. Our aim was to distinguish the extent of the drug-drug interactions between DRV/r and DTG, and to evaluate the consequences of this interaction, in adolescents at steady state. Design: SMILE (PENTA 17-ANRS152) was a phase II/III trial assessing the safety and efficacy of once-daily dual therapy, using dolutegravir (DTG) combined with ritonavir-boosted darunavir (DRV/r), in virologically suppressed adolescents aged 12 years and older. Methods: A joint population pharmacokinetic model for DTG and DRV/r was developed with prior individual drug models (involving unbound and total concentrations) using SMILE data. Results: Unbound DRV exposure, integrated as a power function on unbound DTG clearance best described DRV/r inhibition of DTG elimination. Nevertheless, no interaction was identified between DRV/r and total DTG clearance. Moreover, the influence of unbound DRV exposures to predict unbound DTG concentrations was relatively small. Conclusion: Administration of DRV/r 800/100 mg and DTG 50 mg once daily provides adequate concentrations and exposures with no clinically relevant drug-drug interactions at steady-state.
Archive Staff Only
 |
View Item |
